newsfilter
← Latest News
GlobeNewswire·

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase